MA27544A1 - Conjugues de l'hormone de croissance humaine chimiquement modifies. - Google Patents

Conjugues de l'hormone de croissance humaine chimiquement modifies.

Info

Publication number
MA27544A1
MA27544A1 MA27686A MA27686A MA27544A1 MA 27544 A1 MA27544 A1 MA 27544A1 MA 27686 A MA27686 A MA 27686A MA 27686 A MA27686 A MA 27686A MA 27544 A1 MA27544 A1 MA 27544A1
Authority
MA
Morocco
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hormone conjugates
Prior art date
Application number
MA27686A
Other languages
English (en)
Inventor
Rory F Finn
Ned R Siegel
Wei Liao
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MA27544A1 publication Critical patent/MA27544A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugués de l'hormone de croissance humaine chimiquement modifiés La présente invention décrit une hormone de croissance humaine (hGH) modifiée chimiquement par liaison de la protéine avec un polymère soluble dans l'eau. La protéine modifiée au sens de l'invention, présente une activité hGH qui dure beaucoup plus longtemps que celle de l'hormone non modifiée, ce qui permet d'en réduire la dose et la fréquence d'administration.
MA27686A 2001-11-20 2004-05-19 Conjugues de l'hormone de croissance humaine chimiquement modifies. MA27544A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
MA27544A1 true MA27544A1 (fr) 2005-10-03

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27686A MA27544A1 (fr) 2001-11-20 2004-05-19 Conjugues de l'hormone de croissance humaine chimiquement modifies.

Country Status (25)

Country Link
EP (1) EP1453859A2 (fr)
JP (2) JP2005525302A (fr)
KR (2) KR20050044858A (fr)
CN (1) CN1608079A (fr)
AP (1) AP2004003050A0 (fr)
AU (1) AU2002356990A1 (fr)
BR (1) BR0214451A (fr)
CA (1) CA2467731A1 (fr)
CO (1) CO5580794A2 (fr)
EA (2) EA008505B1 (fr)
EC (1) ECSP045114A (fr)
GE (1) GEP20063860B (fr)
HR (1) HRP20040448A2 (fr)
HU (1) HUP0500997A2 (fr)
IL (1) IL162031A0 (fr)
IS (1) IS7268A (fr)
MA (1) MA27544A1 (fr)
MX (1) MXPA04004809A (fr)
NO (1) NO20042182L (fr)
OA (1) OA13063A (fr)
PL (1) PL374354A1 (fr)
RS (1) RS53104A (fr)
TN (1) TNSN04090A1 (fr)
WO (1) WO2003044056A2 (fr)
ZA (1) ZA200403907B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (fr) * 2001-12-11 2006-05-17 Sun Bio Inc Nouveaux aldehydes de polyethyleneglycol monofonctionnels
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DK3025726T3 (da) * 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
EP1591467A1 (fr) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugue d un polyethylene glycol comprenant un group terminal alcanal et un hormone de croissance humaine
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035553A2 (fr) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugaison de peptides
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
JP2008511610A (ja) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
AU2005323106B2 (en) * 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
WO2006084888A2 (fr) 2005-02-10 2006-08-17 Novo Nordisk A/S Hormones de croissance pegylees a leur extremite c
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
CN101268098A (zh) * 2005-08-30 2008-09-17 诺沃-诺迪斯克保健股份有限公司 聚乙二醇化生长激素的液体制剂
SI1954710T1 (sl) 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
WO2008003750A2 (fr) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag Nouveaux conjugués de protéines et leurs procédés de préparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
WO2008049920A2 (fr) 2006-10-26 2008-05-02 Novo Nordisk A/S Variantes il-21
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
JP5458416B2 (ja) * 2008-04-03 2014-04-02 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽－聚合物綴合物
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
CA2747825A1 (fr) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Composes stables d'hormone de croissance
EP2461831B1 (fr) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Hormones de croissance ayant une efficacité in vivo prolongée
CA2783296C (fr) 2009-12-15 2019-01-15 Ascendis Pharma As Composition d'hormone de croissance
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (fr) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (fr) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Formulation d'un composé d'hormone de croissance
CA2964390A1 (fr) 2014-11-06 2016-05-12 Pharmaessentia Corporation Regime posologique pour l'interferon pegyle
ES2947818T3 (es) 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Nuevos profármacos poliméricos de la HCh
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
MX391071B (es) * 2015-03-11 2025-03-21 Nektar Therapeutics Conjugados de un resto de il-7 y un polímero.
NZ740534A (en) 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
EP3934625A1 (fr) 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Formes posologiques d'hormone de croissance à action prolongée ayant une efficacité supérieure à une dose de somatropine quotidienne
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
WO1992016555A1 (fr) * 1991-03-18 1992-10-01 Enzon, Inc. Conjuges de polypeptides et de glycopolypeptides associes a des polymeres, contenant de l'hydrazine
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
HK1049673A1 (zh) * 1999-01-29 2003-05-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (fr) * 2001-01-11 2002-07-18 Maxygen Aps Molecules d'hormone de croissance ameliorees

Also Published As

Publication number Publication date
CO5580794A2 (es) 2005-11-30
AP2004003050A0 (en) 2004-06-30
ECSP045114A (es) 2004-07-23
AU2002356990A1 (en) 2003-06-10
NO20042182L (no) 2004-08-11
ZA200403907B (en) 2007-12-27
CA2467731A1 (fr) 2003-05-30
PL374354A1 (en) 2005-10-17
HRP20040448A2 (en) 2006-02-28
HUP0500997A2 (en) 2007-11-28
WO2003044056A3 (fr) 2003-08-21
JP2006321808A (ja) 2006-11-30
JP2005525302A (ja) 2005-08-25
OA13063A (en) 2006-11-10
EP1453859A2 (fr) 2004-09-08
GEP20063860B (en) 2006-06-26
BR0214451A (pt) 2006-05-30
MXPA04004809A (es) 2004-08-11
WO2003044056A2 (fr) 2003-05-30
IL162031A0 (en) 2005-11-20
EA008505B1 (ru) 2007-06-29
KR20050044858A (ko) 2005-05-13
IS7268A (is) 2004-05-17
EA200700431A1 (ru) 2008-02-28
KR20070072924A (ko) 2007-07-06
CN1608079A (zh) 2005-04-20
EA200400565A1 (ru) 2005-06-30
RS53104A (sr) 2006-10-27
TNSN04090A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
TNSN04090A1 (fr) Conjugues de l'hormone de croissance humaine chimiquement modifies
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
WO2004050016A3 (fr) Administration d'agents pharmaceutiques par l'intermediaire du recepteur humain de l'insuline
WO1998051325A3 (fr) Peptides aleatoires se liant au recepteurs de transport du tractus gastrointestinal (git) et procedes y relatifs
ATE383375T1 (de) Wti-modifiziertes peptid
EP2278003A3 (fr) Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
ATE68976T1 (de) Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.
DE69010206D1 (de) Stabilisierte protein- oder peptidkonjugate.
EA199900979A1 (ru) Композиции активированного протеина
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
BG104070A (en) Chimeric protein of interleukin-6, soluble receptor/ligand, its analogues and their application
EE200100507A (et) Hüdroksümatairesinool vähkkasvaja vältimises
IL205802A (en) Training bracelets containing a constant region of immunoglobulin and a molecule with biological activity
DK1146896T3 (da) Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
WO2003103585A3 (fr) Methodes de traitement de l'angiogenese, de la croissance tumorale et de metastases
EA200100905A1 (ru) Фармацевтическая композиция, содержащая ингибиторы протонного насоса
EP1071443A4 (fr) Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
WO2000006185A3 (fr) Procedes d'utilisation d'un analogue de somatostatine
FR2821359B1 (fr) L'heterocarpine, une proteine fixant le ghrh humain
EA200600331A1 (ru) Применение человеческого гормона роста при множественной системной атрофии
WO2003096964A3 (fr) Moyens et procedes de traitement de maladies liees ou dues a des niveaux non physiologiques de pp2ac associee aux microtubules
ATE282704T1 (de) Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1)